{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:32:39Z","timestamp":1747164759739,"version":"3.40.5"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jfo.2024.104177","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T09:18:22Z","timestamp":1712740702000},"page":"104177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cognitive bias evaluation on the choice of treatment in common retinal disorders among retina specialists in 2023"],"prefix":"10.1016","volume":"47","author":[{"given":"L.-J.","family":"Niegowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.Y.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Crincoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6758-7972","authenticated-orcid":false,"given":"C.J.","family":"Mehanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.H.","family":"Souied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2024.104177_bib0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1167\/iovs.62.14.26","article-title":"Retinal and choroidal vascular diseases: past, present, and future: the 2021 proctor lecture","volume":"62","author":"Campochiaro","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jfo.2024.104177_bib0075","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.2147\/DDDT.S295223","article-title":"Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration","volume":"15","author":"Hussain","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jfo.2024.104177_bib0080","doi-asserted-by":"crossref","DOI":"10.1159\/000525653","article-title":"Is there a dose-response relationship? Real-world outcomes of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration","author":"Shor","year":"2022","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.jfo.2024.104177_bib0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.oret.2021.08.009","article-title":"Treatment of neovascular age-related macular degeneration: an economic cost-risk analysis of anti-vascular endothelial growth factor agents","volume":"6","author":"Moisseiev","year":"2022","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2024.104177_bib0090","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jfo.2024.104177_bib0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ophtha.2019.10.005","article-title":"A collaborative retrospective study on the efficacy and safety of intravitreal dexamethasone implant (ozurdex) in patients with diabetic macular edema: the European DME registry study","volume":"127","author":"Rosenblatt","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2024.104177_bib0100","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/bjophthalmol-2020-317306","article-title":"Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal ozurdex injections","volume":"105","author":"Gale","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104177_bib0105","doi-asserted-by":"crossref","first-page":"6800","DOI":"10.1038\/s41598-022-10961-y","article-title":"Baseline predictors for good visual gains after anti-vascular endothelial growth factor therapy for myopic choroidal neovascularization","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfo.2024.104177_bib0110","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14740338.2021.1952979","article-title":"Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization","volume":"21","author":"Ng","year":"2022","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jfo.2024.104177_bib0115","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jfo.2024.104177_bib0120","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1136\/bjophthalmol-2015-307849","article-title":"Retina specialists treating cystoid macular oedema secondary to retinal vein occlusion recommend different treatments for patients than they would choose for themselves","volume":"100","author":"Wang","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jfo.2024.104177_bib0125","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1097\/IAE.0000000000002351","article-title":"Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab","volume":"39","author":"Bavinger","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2024.104177_bib0130","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2018.3939","article-title":"Association of acute endophthalmitis with intravitreal injections of corticosteroids or anti-vascular growth factor agents in a nationwide study in France","volume":"136","author":"Baudin","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551224001220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T10:40:32Z","timestamp":1712745632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551224001220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0181551224001220"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104177","relation":{},"ISSN":["0181-5512"],"issn-type":[{"type":"print","value":"0181-5512"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive bias evaluation on the choice of treatment in common retinal disorders among retina specialists in 2023","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2024.104177","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104177"}}